Protara Therapeutics, Inc. (FRA:1KPA)

Market Cap	223.72M
Revenue (ttm)	n/a
Net Income (ttm)	-45.09M
Shares Out	n/a
EPS (ttm)	-1.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	23
Open	6.35
Previous Close	6.30
Day's Range	6.35 - 6.35
52-Week Range	2.26 - 9.15
Beta	n/a
RSI	69.57
Earnings Date	Mar 9, 2026

About Protara Therapeutics

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headqu...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Jesse Shefferman
• Employees: 33
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1KPA

Financial Performance

Financial numbers in USD